Coherent Biopharma

CBP-1008 has been developed utilizing our first-generation Bi-XDC platform technology. It represents a pioneering Bi-XDC targeting FRα and TRPV6, with monomethyl auristatin E (MMAE) as payload. In contrast to ADCs, Bi-XDCs exhibit smaller molecular sizes, enhanced tissue permeability, lower immunogenicity, shorter elimination half-lives, and reduced manufacturing costs. Moreover, the synergistic effect of the bi-specific ligands in CBP-1008 notably enhances drug delivery performance. Preclinical

PROC LC Pancreatic cancer Esophagus cancer

√ Dual tumor antigen targeting √ Retains specificity / affinity √ Cover Low Receptor expressions √ Broad Indications

At the 14th World ADC Conference, Coherent Biopharma’s CEO, Dr. Robert Huang, presented clinical data on CBP-1008, highlighting the broad benefits of its Bi-XDC technology across diverse patient groups.

March 13th-16th，2023, London｜Invited by the Annual World ADC committee, Dr. Robert HUANG, the Founder and CEO of Coherent Biopharma Group attended the 13th Annual World ADC London and delivering a speech on advances of company’s 2nd-Gen Bi-XDC pipeline on the Pre-Conference Seminar Day.

The U.S. FDA granted Orphan Drug Designation to Coherent Biopharma’s second-generation dual-ligand drug, CBP-1019, for pancreatic cancer treatment in September 2023.

CBP-1018 is the first dual-ligand conjugate drug targeting PSMA and FRα developed on Coherent Biopharma (CBP)’s Bi-XDC technology platform. Recently, CBP announced that the company has successfully achieved its goals of CBP-1018 Phase I clinical trial in China.

Guitao, Wang leads the R&D project management and pipeline development of Coherent Biopharma.

Jun, Shao is responsible for overseeing the company’s operations in the US, regulatory submissions and registrations, quality assurance and control systems, clinical drug supply, product pipeline development, and overall company operations.

Mingming, Yan is responsible for overseeing corporate business operations and clinical operations administration.

Coherent Biopharma, founded in 2016, develops and commercializes bi-targeting XDC drugs, with a management team experienced in biotechnology R&D, medicinal chemistry, clinical studies, and global business development.

1 Proprietary Platform Technology 5+ First-in-Class Assets 15+ Global IP Protection